Most studies exploring the effects of adiponectin, however, have used transplant models of advanced PDAC cells to demonstrate that activation of adiponectin signaling (e.g., with the agonist AdipoRon) decreases orthotopic tumor growth by opposing leptin action (Messaggio et al, 2017). This evidence concerns the gene ADIPOQ and neoplasm.